How Shapa helps you maintain your weight, on a GLP-1 and after.

Obesity is a chronic disease, so what keeps your weight steady changes as your treatment does. Choose your situation.

Shapa Health · Updated November 2026 · 4-minute read

On a GLP-1 After it ends Your range Treatment ends
Shapa Numberless Scale next to its mobile app

What’s happening in your body

While you take a GLP-1, it acts on appetite and fullness signals and quiets much of your body’s pushback against weight loss. In SURMOUNT-4, people who kept taking their medication held their loss and lost a further 5.5%.

SURMOUNT-4: continuing vs stopping tirzepatide

Kept taking tirzepatide −5.5% Switched to placebo +14.0% −5% 0% +5% +10%
Change in body weight from week 36 to week 88. Before this, all participants lost an average of 20.9% over 36 weeks on tirzepatide.

What Shapa does for you now

Step on the Numberless Scale each morning and see your trend as a color instead of a number. The Shapa app turns that trend into small daily missions, personalized to you.

  • Start the daily check-in now One step on the scale each morning becomes routine, so it’s already in place when your treatment changes.
  • See progress when the scale slows Your color shows the direction of your trend, which keeps you going through plateaus as weight loss levels off.
  • Practice the habits that last The app’s daily missions are small actions personalized to you, practiced while the medication is helping.
  • Bring your trend to appointments Weeks of check-ins give you and your doctor something concrete to discuss when you plan a maintenance dose.

Ask your doctor

  • Should I stay on a maintenance dose, and for how long?
  • If I reduce or stop, how should we taper, and when should we check in?
  • What change in my weight trend should prompt a call?
  • How much protein and strength training do I need to protect muscle?

87% of Shapa members use Shapa 5 or more times a week, as reported by Shapa.

Common questions

Will I regain weight if I stop my GLP-1?

Many people do. In the STEP 1 trial extension, people regained about two-thirds of their weight loss within a year of stopping. Results vary from person to person, and a maintenance plan helps you spot drift early.

How can Shapa help after my GLP-1 treatment ends?

Shapa keeps your daily check-in going. One step on the Numberless Scale shows your trend as a color, so an upward drift shows up early, and the app’s daily missions keep your habits going once the medication’s help fades.

Is regaining weight after a GLP-1 a failure?

No. Obesity is a chronic, relapsing disease, and regain reflects biology, not willpower. Treat it as a signal to adjust your plan with your doctor.

Does Shapa replace my medication or my doctor?

No. Shapa supports daily habits alongside the care plan you make with your doctor. It doesn’t prescribe or change medication.

Shapa has a journey for people on, or coming off, GLP-1s

Take the Shapa Assessment to start the journey that matches your situation.

Start Assessment →
Get 70% Off a Lifetime Membership → Pay once. Never pay again. Use code PAYONCE at checkout.
HSA/FSA eligible

Sources

  1. American Medical Association. Resolution recognizing obesity as a disease, 2013.
  2. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. Obesity Reviews, 2017.
  3. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. PubMed .
  4. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction: the SURMOUNT-4 randomized clinical trial. JAMA, 2024. JAMA .
  5. Butryn ML, et al. Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity, 2007.
  6. Shapa member figures as reported on myshapa.com.

Important: This guide is general education, not medical advice. GLP-1 medications are prescription drugs and aren't right for everyone. Talk with your doctor before starting, stopping or changing any treatment.